{"task_id": "43d6c78454ace298", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 228/464)", "text": " survival\nbefore recurrence\nEndometrial Cancer\n217\n\n--- Page 239 ---\nMANAGEMENT (CONT\u2019D)\n\u0002\nCHEMOTHERAPY\nregimens include carboplatin pa\nclitaxel, paclitaxel doxorubicin carboplatin (TAP),\npaclitaxel doxorubicin cisplatin,\nand\npaclitaxel\ndoxorubicin. Highest response rate is \b55% with\nTAP. TAP is the only regimen associated with a\nsurvival benefit in clinical trial\nTREATMENT ISSUES\nINDICATIONS FOR PELVIC AND PARAAORTIC LYM\nPHADENECTOMY\nthis is an area of controversy.\nTwo large trials have demonstrated no therapeutic\nbenefit to lymphadenectomy. This has not been uni\nformally accepted by the surgical community\nINDICATIONS FOR PRIMARY RADIOTHERAPY\nelderly or women with multiple comorbidities and\ncannot tolerate. Outcome inferior to surgery\nCervical Cancer\nPATHOPHYSIOLOGY\nHISTOLOGIC TYPE\n\u0002\nSQUAMOUS (80%)\nstarts at squamocolumnar junc\ntion. Slow progression from CIN to carcinoma over\n15 years\n\u0002\nADENOCARCINOMA (20%)\n\u0002\nSARCOMA\nHPV AND CERVICAL CANCER\ntypes 16, 18, 45, 31,\n33, 52, 58, 35 are associated with cervical cancer, and\ntype 18 is particularly strongly associated with poorly\ndifferentiated carcinoma with nodal metastases. Viral\nproteins implicated in carcinogenesis include E6 and\nE7. Types 6 and 11 are usually associated with con\ndyloma acuminate\nRISK FACTORS\nearly age at first intercourse, early\nfirst pregnancy, multiple sexual partners, male part\nners with multiple sexual partners, venereal diseases\n(especially HPV related), HIV, smoking\nCLINICAL FEATURES\nSYMPTOMS\n\u0002\nLOCOREGIONAL\nmay be asymptomatic, abnormal\nvaginal bleeding, postcoital spotting, vaginal dis\ncharge (may be malodorous), pelvic pain\n\u0002\nMETASTATIC\ncough, jaundice, bony pain\n\u0002\nCONSTITUTIONAL\nweight loss, anorexia, fatigue\nRelated Topic\nCancer Screening (p. 222)\nTNM STAGING\nTNM STAGING\nT stage\n\u0002 T1a=microscopic only (T1a1=stromal invasion\n\u00043 mm\nand\n\u00047 mm\nin lateral\nspread,\nT1a2=stromal invasion 3 5 mm and \u00047 mm in\nlateral spread)\n\u0002 T1b=microscopic\nor\nmacroscopic\n(T1b1=\n\u00044 cm, T1b2 >4 cm)\nTNM STAGING (CONT\u2019D)\n\u0002 T2=beyond\ncervix\nbut\nnot\npelvic\nwall\n(T2a=proximal 2/3 of vagina, T2b=with parame\ntrial invasion)\n\u0002 T3=invades distal vagina, pelvic wall, or causes\nhydronephrosis (T3a=lower third of vagina,\nT3b=extends\nto\npelvic\nwall\nor\ncauses\nhydronephrosis)\n\u0002 T4=spread to bladder or rectum\nN stage\n\u0002 N1=regional LN\nM stage (lung, liver, bone)\n\u0002 M1=distant metastasis\nSTAGE GROUPINGS\nStage\nTNM @=any\n5 year\nsurvival\nIA1\nIA2\nIB1\nIB2\nT1a1N0M0\nT1a2N0M0\ng\nT1b1N0M0\nT1b2N0M0\ng\n95%\n80%\nIIA\nIIB\nT2aN0M0\nT2bN0M0\ng\n60%\nIIIA\nIIIB\nT3aN0M0\nT3bN@M0, T1a1 3aN1M0g\n30%\nIVA\nIVB\nT4N@M0\nT@N@M1\ng\n5%\nINVESTIGATIONS\nBASIC\n\u0002\nBLOOD TESTS\nCBCD, lytes, urea, Cr, AST, ALT,\nALP, bili\n\u0002\nIMAGING\nCXR, CT abd/pelvis\n\u0002\nSPECIAL\npap smear ! if lesion suspected, col\nposcopy,\ncone\nbiopsy,\nloop\nelectrosurgical\nexcision, endocervical curettage\nMANAGEMENT\nSTAGE IA1\nsimple hysterectomy, excisional con\nization. If lymphovascular invasion, treat as IA2\ndisease\n218\nCervical Cancer", "text_length": 2939, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 228/464)", "type": "chunk", "chunk_index": 227, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.560625", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.561414", "status": "complete", "chunks_added": 2}